Here's what you need to know about the four CFTR (cystic fibrosis transmembrane conductance regulator) modulators.
Site Search
New Effort Will Search for Potential Therapies Targeting the Most Common Mutation of Cystic Fibrosis
Kalydeco Marks the Latest Success of the Cystic Fibrosis Foundation’s Venture Philanthropy Model
CF Foundation Provided Scientific, Clinical and Significant Funding Support in Drug Development Process
Today, the Cystic Fibrosis Foundation announced that it has awarded up to $400,000 to Life Edit Therapeutics Inc. to explore the application of their unique gene editing technology in CF.
The Cystic Fibrosis Foundation is awarding up to $15.9 million in additional funding to Eloxx Pharmaceuticals Inc. to expand clinical studies of ELX-02, a potential therapy for people with CF who have nonsense mutations.
Potential treatment from Calithera Biosciences minimizes growth of germs in the lungs
New modulators in development by the CF-specific company could provide unique treatment options for the underlying cause of cystic fibrosis for many people with the disease